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Background & Aims: Psychological treatment and the efficacy of drug therapy are considered to be useful 
in quality of life and symptoms of patients with irritable bowel syndrome. The aim of this study was to 
examine the effects of cognitive-behavior therapy associated with drug therapy in comparison to drug 
therapy alone on the quality of life and symptoms of IBS patients with diarrhea predominance. 
Method: This study was a randomized clinical trial on 64 IBS patients. The patients were selected according 
to Rome-III criteria, and were divided into the two groups. Bowel Symptoms Severity and Frequency Scale 
(BSS-FS) and Quality Of Life (QOL-IBS) were used for evaluation of patients’ symptoms. The first group 
underwent cognitive-behavior therapy with medication therapy, and the second group only received 
medication. Data were analyzed using analysis of multiple covariances (MANCOVA). 
Results: The two groups showed significant difference in the QOL-IBS in post treatment and follow-up 
stages (P<0/05). There were significant differences in the severity and frequency of IBS symptoms between 
the two groups after the study period (P < 0.05). However, no significant difference was observed at follow-
up stage between the two groups (P > 0.05). 
Conclusion: Cognitive-behavior therapy associated with drug therapy can be useful in IBS patients with 
diarrhea predominance. However, stopping this treatment may lead to recurrence of the symptoms. 
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